Concepedia

Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a <i>PCM1-JAK2</i> Fusion Gene

Elisa Rumi, Jelena D. Milosevic Feenstra, Ilaria Carola Casetti, Irene Dambruoso, Daniela Pietra, Emanuela Boveri, Marina Boni, Paolo Bernasconi, Francesco Passamonti, Róbert Královics,

Journal of Clinical Oncology · 2013 · 57 citations · 10 references

DOI

Concepts

References

10

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature · 2005 · 3.5K citations

, , +7

A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders

Róbert Královics, Francesco Passamonti, Andreas Buser et al. · New England Journal of Medicine · 2005 · 3.5K citations · Full text

, , +15

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

, , +12

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · New England Journal of Medicine · 2012 · 1.8K citations · Full text

, , +10

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa et al. · New England Journal of Medicine · 2010 · 1.2K citations · Full text

, , +13